In a report released today, Amit Dayal from H.C. Wainwright maintained a Buy rating on Amyris (AMRS), with a price target of $11. The company’s shares closed yesterday at $4.83.
“We expect the company’s topline to grow at a seven-year CAGR of 26.3% from $159.6M in 2018 to $819.1M in 2025. We expect mid- to long-term overall gross margins to fluctuate between 60-70%, driven by lumpiness of the high margin revenues from grants and collaboration. We are projecting operating expenses to grow at a seven-year CAGR of 5.0% from 2018 to 2025. We expect the company to generate positive net profit beginning in 2020.”
According to TipRanks.com, Dayal ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.0% and a 28.4% success rate. Dayal covers the Industrial Goods sector, focusing on stocks such as Ballard Power Systems, Capstone Turbine Corp, and Orion Energy Systems.
Amyris has an analyst consensus of Moderate Buy, with a price target consensus of $9.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.29 and a one-year low of $3.11. Currently, Amyris has an average volume of 1.28M.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AMRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amyris, Inc. is an industrial biotechnology company, which engages in the provision of bioscience solutions. It focuses on the research, development, manufacture, and sale of fuels and farnesene-derived products. Its products include cosmetics, flavors and fragrances, performance materials, diesel, jet fuel, and lubricants. The company was founded by Jack D.